Pioglitazone, Vitamin E, Or Placebo For Nonalcoholic Steatohepatitis
| Effect | Decrease |
| Trial Design | Double blind |
| Trial Length | 6+ Months |
| Number of Subjects | 222 |
| Sex | Both Genders |
| Age Range | 30-44, 45-64 |
| Body Types | Obese |
Supplementation of 800 IU vitamin E (as alpha-tocopherol) daily for 96 weeks in persons with non-alcoholic fatty liver disease (NAFLD) appeared to reduce circulating ALT and liver fat scores in approximately 50% of the group (more than placebo) although liver fibrosis was not affected.
